News

Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
BioSpace11h
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
STAT6h
Inside an FDA drug rejection, and layoffs at Sarepta
Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...
Thursday movers: Taiwan Semi, Sarepta Therapeutics, MP Materials
TSMC shares rose 4% in premarket trade as the contract chip manufacturer lifted its 2025 sales guidance. Sarepta Therapeutics stock jumped 34% as the company set plans to lay off more than a third of ...
Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SRPT
Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover ...
STAT1d
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...
Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients
Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, ...